Glucuronides in Anti-Cancer Therapy

Title: Glucuronides in Anti-Cancer Therapy

Volume: 3 Issue: 2

Author(s): Xi Chen, Bingyuan Wu and Peng George Wang

Affiliation:

Keywords: glucuronides, anti cancer therapy, glucuronide prodrug, prodrug monotherapy, antibody directed enzyme prodrug therapy, combined chemo radiotherapy

Abstract: Glucuronide prodrugs have shown promising efficacy in anti-cancer therapy due to their increased specificity and reduced systemic toxicity. The prodrugs can be used in prodrug monotherapy (PMT), which is based on elevated tumor β-glucuronidase activity. β-Glucuronidase activates the low-toxic prodrugs into highly cytotoxic agents specifically in the tumor site. The specificity of the prodrugs can be further improved by combined use with monoclonal antibodies against tumor-specific antigens, namely antibody-directed enzyme prodrug therapy (ADEPT), and the potency of the prodrugs can be greatly enhanced with the incorporation of an appropriate radionuclide in the combined chemo- and radio-therapy of cancer (CCRTC) strategy. The prodrugs can also be utilized to modify liposomes for efficient delivery of anti-cancer drugs.

Cite this article as:

Chen Xi, Wu Bingyuan and Wang George Peng, Glucuronides in Anti-Cancer Therapy, Current Medicinal Chemistry - Anti-Cancer Agents 2003; 3 (2) . https://dx.doi.org/10.2174/1568011033353470